Emeline Christophel-Plathier1*, Vitor Mendes2, Francois Verdy2, Sylvain Mauron1 and Caroline Mury1
1Department Anesthesiology, Lausanne University Hospital (CHUV), Switzerland
2Department Cardiac Surgery, Lausanne University Hospital (CHUV), Switzerland
Cardiac surgery with Cardiopulmonary Bypass (CPB) is a trigger of significant Systemic Inflammatory Response Syndrome (SIRS) with an accompanying cytokine release. Additional factors increasing the risk of post-operative SIRS include surgery itself, long CPB duration, and mechanical hemolysis and ischemia-reperfusion injuries. Cytosorb® is a hemoadsorption device that removes many cytokines from the blood. Pediatric patients with exaggerated pre-operative SIRS might be good candidates for an assessment of Cytosorb’s® usefulness. We present the case of a fullterm newborn with a hypoplastic left heart syndrome. Five days after birth, the patient underwent a Norwood stage I palliation under CPB with adjunction of Cytosorb®. Post-operative course was uneventful, hemodynamic adaptation was good, with rapid weaning off all amine infusions.
Christophel-Plathier E, Mendes V, Verdy F, Mauron S, Mury C. First Hemoadsorption during Cardiopulmonary Bypass in Neonate with Complex Cardiac Malformation. Ann Clin Case Rep. 2022; 7: 2257.